Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
PMV Pharmaceuticals, Inc
Mayo Clinic
University of California, Davis
Bicara Therapeutics
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Wisconsin, Madison
Neonc Technologies, Inc.
Universität des Saarlandes
Seagen Inc.
Merus B.V.
Fujian Medical University
Tizona Therapeutics, Inc
Genentech, Inc.
BioNTech SE
Institut Claudius Regaud
Emory University
IDEAYA Biosciences
Ohio State University Comprehensive Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
Wake Forest University Health Sciences
VLP Therapeutics
Big Ten Cancer Research Consortium
University of Chicago
VM Oncology, LLC
Memorial Sloan Kettering Cancer Center
Alpha Tau Medical LTD.
University of Chicago
Inhibrx Biosciences, Inc
Vanderbilt-Ingram Cancer Center
National Institutes of Health Clinical Center (CC)
Rakuten Medical, Inc.
Maastricht University Medical Center
National University Hospital, Singapore
Scancell Ltd
Taipei Veterans General Hospital, Taiwan
Saint Petersburg State University, Russia
Epkin
Bicara Therapeutics
Jonsson Comprehensive Cancer Center
University of Wisconsin, Madison
Dana-Farber Cancer Institute
Iovance Biotherapeutics, Inc.
Rapa Therapeutics LLC
Precision Biologics, Inc
Istituti Clinici Scientifici Maugeri SpA
TiumBio Co., Ltd.